|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vogel A, Meyer T, Sapisochin G, Salem R
and Saborowski A: Hepatocellular carcinoma. Lancet. 400:1345–1362.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lubel JS, Roberts SK, Strasser SI,
Thompson AJ, Philip J, Goodwin M, Clarke S, Crawford DH, Levy MT
and Shackel N: Australian recommendations for the management of
hepatocellular carcinoma: A consensus statement. Med J Aust.
214:475–483. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ng CKY, Dazert E, Boldanova T,
Coto-Llerena M, Nuciforo S, Ercan C, Suslov A, Meier MA, Bock T,
Schmidt A, et al: Integrative proteogenomic characterization of
hepatocellular carcinoma across etiologies and stages. Nat Commun.
13:24362022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Younossi ZM and Henry L: Epidemiology of
non-alcoholic fatty liver disease and hepatocellular carcinoma.
JHEP Rep. 3:1003052021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mocan L: Multimodal therapy for
hepatocellular carcinoma: The role of surgery. Eur Rev Med
Pharmacol Sci. 25:4470–4477. 2021.PubMed/NCBI
|
|
7
|
Wen N, Cai Y, Li F, Ye H, Tang W, Song P
and Cheng N: The clinical management of hepatocellular carcinoma
worldwide: A concise review and comparison of current guidelines:
2022 update. Biosci Trends. 16:20–30. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Arita J, Ichida A, Nagata R, Mihara Y,
Kawaguchi Y, Ishizawa T, Akamatsu N, Kaneko J and Hasegawa K:
Conversion surgery after preoperative therapy for advanced
hepatocellular carcinoma in the era of molecular targeted therapy
and immune checkpoint inhibitors. J Hepatobiliary Pancreat Sci.
29:732–740. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yin Z, Chen D, Liang S and Li X:
Neoadjuvant therapy for hepatocellular carcinoma. J Hepatocell
Carcinoma. 9:929–946. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Makary MS, Khandpur U, Cloyd JM, Mumtaz K
and Dowell JD: Locoregional therapy approaches for hepatocellular
carcinoma: Recent advances and management strategies. Cancers
(Basel). 12:19142020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Affonso BB, Galastri FL, da Motta Leal
Filho JM, Nasser F, Falsarella PM, Cavalcante RN, de Almeida MD,
Felga GEG, Valle LGM and Wolosker N: Long-term outcomes of
hepatocellular carcinoma that underwent chemoembolization for
bridging or downstaging. World J Gastroenterol. 25:5687–5701. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Parikh ND, Waljee AK and Singal AG:
Downstaging hepatocellular carcinoma: A systematic review and
pooled analysis. Liver Transpl. 21:1142–1152. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Melchiorre F, Patella F, Pescatori L,
Pesapane F, Fumarola E, Biondetti P, Brambillasca P, Monaco C,
Ierardi AM and Franceschelli Gand Carrafiello G: DEB-TACE: A
standard review. Future Oncol. 14:2969–2984. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cai L, Li H, Guo J, Zhao W, Duan Y, Hou X,
Cheng L, Du H, Shao X, Diao Z and Li C: Drug-eluting bead
transarterial chemoembolization is an effective downstaging option
for subsequent radical treatments in patients with hepatocellular
carcinoma: A cohort study. Clin Res Hepatol Gastroenterol.
45:1015352021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gandhi L, Rodriguez-Abreu D, Gadgeel S,
Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ,
Powell SF, et al: Pembrolizumab plus chemotherapy in metastatic
non-small-cell lung cancer. N Engl J Med. 378:2078–2092. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fang W, Yang Y, Ma Y, Hong S, Lin L, He X,
Xiong J, Li P, Zhao H, Huang Y, et al: Camrelizumab (SHR-1210)
alone or in combination with gemcitabine plus cisplatin for
nasopharyngeal carcinoma: Results from two single-arm, phase 1
trials. Lancet Oncol. 19:1338–1350. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Markham A and Keam SJ: Camrelizumab: First
global approval. Drugs. 79:1355–1361. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jin ZC, Zhong BY, Chen JJ, Zhu HD, Sun JH,
Yin GW, Ge NJ, Luo B, Ding WB, Li WH, et al: Real-world efficacy
and safety of TACE plus camrelizumab and apatinib in patients with
HCC (CHANCE2211): A propensity score matching study. Eur Radiol.
Jun 27–2023.(Epub ahead of print). View Article : Google Scholar
|
|
19
|
Zhu C, Dai B, Zhan H and Deng R:
Neoadjuvant transarterial chemoembolization (TACE) plus PD-1
inhibitor bridging to tumor resection in intermediate-stage
hepatocellular carcinoma patients. Ir J Med Sci. 192:1065–1071.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang Y, Zhang Z, Liao W, Hu K and Wang Z:
Combination of sorafenib, camrelizumab, transcatheter arterial
chemoembolization, and stereotactic body radiation therapy as a
novel downstaging strategy in advanced hepatocellular carcinoma
with portal vein tumor thrombus: A case series study. Front Oncol.
11:6503942021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kudo M, Ueshima K, Ikeda M, Torimura T,
Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, et al:
Randomized, open label, multicenter, phase II trial comparing
transarterial chemoembolization (TACE) plus sorafenib with TACE
alone in patients with hepatocellular carcinoma (HCC): TACTICS
trial. J Clin Oncol. 36:2062018. View Article : Google Scholar
|
|
22
|
Zhu XD, Tang ZY and Sun HC: Targeting
angiogenesis for liver cancer: Past, present, and future. Genes
Dis. 7:328–335. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou J, Sun HC, Wang Z, Cong WM, Wang JH,
Zeng MS, Yang JM, Bie P, Liu LX, Wen TF, et al: Guidelines for
diagnosis and treatment of primary liver cancer in China (2017
Edition). Liver Cancer. 7:235–260. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shvarts O, Lam JS, Kim HL, Han KR, Figlin
R and Belldegrun A: Eastern Cooperative Oncology Group performance
status predicts bone metastasis in patients presenting with renal
cell carcinoma: Implication for preoperative bone scans. J Urol.
172:867–870. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Palmieri C and Macpherson IR: A review of
the evidence base for utilizing Child-Pugh criteria for guiding
dosing of anticancer drugs in patients with cancer and liver
impairment. ESMO Open. 6:1001622021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ma Y, Zhao C, Zhao H, Li H, Chen C, Xiang
H, Zheng C, Ma C, Luo C, Qiu H, et al: Comparison of treatment
efficacy and safety between drug-eluting bead transarterial
chemoembolization with CalliSpheres® microspheres and
conventional transarterial chemoembolization as first-line
treatment in hepatocellular carcinoma patients. Am J Transl Res.
11:7456–7470. 2019.PubMed/NCBI
|
|
27
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu J, Shen J, Gu S, Zhang Y, Wu L, Wu J,
Shao G, Zhang Y, Xu L, Yin T, et al: Camrelizumab in combination
with apatinib in patients with advanced hepatocellular carcinoma
(RESCUE): A nonrandomized, open-label, phase II Trial. Clin Cancer
Res. 27:1003–1011. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Qin S, Ren Z, Meng Z, Chen Z, Chai X,
Xiong J, Bai Y, Yang L, Zhu H, Fang W, et al: Camrelizumab in
patients with previously treated advanced hepatocellular carcinoma:
A multicentre, open-label, parallel-group, randomised, phase 2
trial. Lancet Oncol. 21:571–580. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Montasser A, Beaufrere A, Cauchy F,
Bouattour M, Soubrane O, Albuquerque M and Paradis V: Transarterial
chemoembolization enhances programmed death 1 and programmed
death-ligand 1 expression in hepatocellular carcinoma.
Histopathology. 79:36–46. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Waidmann O: Recent developments with
immunotherapy for hepatocellular carcinoma. Expert Opin Biol Ther.
18:905–910. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Han K and Kim JH: Transarterial
chemoembolization in hepatocellular carcinoma treatment: Barcelona
clinic liver cancer staging system. World J Gastroenterol.
21:10327–10335. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gyori GP, Felsenreich DM, Silberhumer GR,
Soliman T and Berlakovich GA: Multimodality locoregional treatment
strategies for bridging HCC patients before liver transplantation.
Eur Surg. 49:236–243. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen J, Hu X, Li Q, Dai W, Cheng X, Huang
W, Yu W, Chen M, Guo Y and Yuan G: Effectiveness and safety of
toripalimab, camrelizumab, and sintilimab in a real-world cohort of
hepatitis B virus associated hepatocellular carcinoma patients. Ann
Transl Med. 8:11872020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mehta N, Frenette C, Tabrizian P, Hoteit
M, Guy J, Parikh N, Ghaziani TT, Dhanasekaran R, Dodge JL,
Natarajan B, et al: Downstaging outcomes for hepatocellular
carcinoma: Results from the multicenter evaluation of reduction in
tumor size before liver transplantation (MERITS-LT) consortium.
Gastroenterology. 161:1502–1512. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Degroote H, Pinero F, Costentin C,
Notarpaolo A, Boin IF, Boudjema K, Baccaro C, Chagas AL, Bachellier
P, Ettorre GM, et al: International study on the outcome of
locoregional therapy for liver transplant in hepatocellular
carcinoma beyond Milan criteria. JHEP Rep. 3:1003312021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jang JW, You CR, Kim CW, Bae SH, Yoon SK,
Yoo YK, Kim DG and Choi JY: Benefit of downsizing hepatocellular
carcinoma in a liver transplant population. Aliment Pharmacol Ther.
31:415–423. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chapman WC, Majella Doyle MB, Stuart JE,
Vachharajani N, Crippin JS, Anderson CD, Lowell JA, Shenoy S, Darcy
MD and Brown DB: Outcomes of neoadjuvant transarterial
chemoembolization to downstage hepatocellular carcinoma before
liver transplantation. Ann Surg. 248:617–625. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Otto G, Herber S, Heise M, Lohse AW, Monch
C, Bittinger F, Hoppe-Lotichius M, Schuchmann M, Victor A and
Pitton M: Response to transarterial chemoembolization as a
biological selection criterion for liver transplantation in
hepatocellular carcinoma. Liver Transpl. 12:1260–1267. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wu X, Gu Z, Chen Y, Chen B, Chen W, Weng L
and Liu X: Application of PD-1 blockade in cancer immunotherapy.
Comput Struct Biotechnol J. 17:661–674. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang F, Qin S, Sun X, Ren Z, Meng Z, Chen
Z, Chai X, Xiong J, Bai Y, Yang L, et al: Reactive cutaneous
capillary endothelial proliferation in advanced hepatocellular
carcinoma patients treated with camrelizumab: Data derived from a
multicenter phase 2 trial. J Hematol Oncol. 13:472020. View Article : Google Scholar : PubMed/NCBI
|
